GLP-1 RA Use Linked to Lower Rates of Hyperkalemia in Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 12, 2024 -- Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and a lower rate of renin-angiotensin system inhibitor (RASi) discontinuation compared with treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) among patients with type 2 diabetes (T2D), according to a study published online Aug. 12 in JAMA Internal Medicine.
Tao Huang, from Peking University in Beijing, and colleagues compared rates of hyperkalemia and RASi persistence among new users of GLP-1 RAs versus users of DPP-4is in a cohort study including adults with T2D who initiated GLP-1 RA or DPP-4i treatment between Jan. 1, 2008, and Dec. 31, 2021. Data were included for 33,280 individuals: 13,633 using GLP-1 RAs and 19,647 using DPP-4is.
The median time receiving treatment was 3.9 months. The researchers found that GLP-1 RA use was associated with a lower rate of any hyperkalemia and moderate-to-severe hyperkalemia compared with DPP-4i use (hazard ratios, 0.61 and 0.52, respectively). Overall, 1,381 of the 21,751 participants using RASis discontinued this therapy. GLP-1 RA use was associated with a lower rate of RASi discontinuation compared with DPP-4i use (hazard ratio, 0.89). In intention-to-treat analyses and across strata of age, sex, cardiovascular comorbidity, and baseline kidney function, results were consistent.
"Treatment with GLP-1 RAs may enable wider use of the guideline-recommended cardioprotective and renoprotective medications and contribute to improving clinical outcomes in this population," the authors write.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
Higher Protein Intake Tied to Lower Mortality in Chronic Kidney Disease
WEDNESDAY, Aug. 21, 2024 -- Higher intake of total, animal, and plant protein is associated with lower mortality in older adults with chronic kidney disease (CKD)...
New Definition of Steatotic Liver Disease Improves Prediction of Kidney Disease
TUESDAY, Aug. 20, 2024 -- Using a new classification of steatotic liver disease (SLD) based on the presence of metabolic dysfunction and alcohol consumption, metabolic...
Modest Gains in Life Expectancy Seen for Dialysis in Older Adults With eGFR
MONDAY, Aug. 19, 2024 -- For older adults, starting dialysis when the estimated glomerular filtration rate (eGFR) falls below 12 mL/min/1.73 m2 results in modest gains in life...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.